The Role of a Combination of Nutraceuticals in the Control of Cardiovascular Risk
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
Cardiovascular risk has been shown to increase with increasing blood pressure values. As a
consequence, it results mandatory to achieve lower blood pressure goals in all hypertensive
patients, taking into account that all drugs always have some side effects that can be very
dangerous and/or uncomfortable for the patients leading to a reduced compliance. Thus,
pharmacological treatment should be delayed until it results really necessary.
The availability of natural substances with a therapeutic action has modified this scenario
because of their reduced potential to cause undesirable effects (compared with drugs). In
order to choose among various nutraceuticals (natural foods compounds with health benefits,
including the prevention and/or treatment of diseases), preference should be given to those
- produced according to the same Good Manufacturing Practice used for drugs, to be sure
that the finished product has a standard, reproducible composition
- for which efficacy and safety in the recommended indications are supported by clinical
trials.
An example of a product with these characteristics is Armolipid Plus, a combination of
nutraceuticals with a demonstrated anti-dyslipidaemic effect. Recently, a large clinical
intervention study showed evidence that treatment with Armolipid Plus leads to a significant
decrease in the overall cardiovascular risk, measured using the Framingham Risk Score.
Progress in Research and Development in this field has led to a new patented and registered
combination of nutraceuticals: Armolipid Prev, containing orthosiphon and CoQ10, with
antihypertensive activity, berberine, red yeast, policosanol and orthosiphon with
antidyslipidaemic effect and folic acid, reducing plasma homocysteine levels.
In addition to the established anti-dyslipidaemic activity of Armolipid plus, Armolipid Prev
has a significant antihypertensive effect, which is beneficial in all those patients with
high blood pressure values without a defined indication to begin a pharmacological treatment
according to the current guidelines. The antihypertensive effect of Armolipid Prev,
documented by ambulatory blood pressure monitoring, in addition to the lowering effect on
dyslipidaemia and even on abdominal girth, represents a new opportunity for complete and
early, effective and safe cardiovascular disease prevention.